Publications by authors named "G E W Fluegen"
Background: Biliary tract cancer (BTC) is one of the most aggressive malignancies and surgery represents the only curative treatment approach. However, even in patients with complete tumor resection 5-year survival rates are below 30%. So far, prognostic markers to assess the outcome of these patients are lacking.
View Article and Find Full Text PDFPurpose: This study aimed to evaluate the prognostic potential of pre-therapeutic [18F]FDG-PET/CT variables regarding prediction of progression-free survival (PFS) and overall survival (OS) in NSCLC-patients.
Method: NSCLC-patients who underwent pre-therapeutic [18F]FDG-PET/CT were retrospectively analyzed. The following imaging features were collected from the primary tumor: tumor size, tumor density, central necrosis, spicules and SUVmax.
Article Synopsis
- The study investigated the extent of mesopancreatic (MP) fat infiltration in patients with distal pancreatic ductal adenocarcinomas (dPDAC) and its impact on surgical outcomes, comparing it to patients with high pancreatic ductal adenocarcinomas (hPDAC).
- Results showed that 75.4% of dPDAC patients had MP fat infiltrated by tumor cells, with similar rates of infiltration and resection margins between dPDAC and hPDAC patients.
- Both resection status and MP infiltration were found to be significant prognostic factors for overall survival in dPDAC patients, highlighting the importance of surgical margin clearance.
Clinically used pan and class I HDACi cause severe side effects, whereas class IIa HDACi are less cytotoxic. Here, we present the synthesis and anticancer effects of a series of 5-(trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based amides and alkoxyamides derived from the previously reported class IIa HDACi YAK540. The most active class IIa inhibitor 1a showed nanomolar inhibition of the class IIa enzymes 4, 5, 7 (IC HDAC4: 12 nM) and high selectivity (selectivity index >318 for HDAC4) over non-class IIa HDACs.
View Article and Find Full Text PDFThe limited sensitivity of circulating tumor cell (CTC) detection in pancreatic adenocarcinoma (PDAC) stems from their extremely low concentration in the whole circulating blood, necessitating enhanced detection methodologies. This study sought to amplify assay-sensitivity by employing diagnostic leukapheresis (DLA) to screen large blood volumes. Sixty patients were subjected to DLA, with a median processed blood volume of ~ 2.
View Article and Find Full Text PDF